This content is machine translated Diffuse large B-cell lymphoma T-cell-based therapy “off the shelf” Two types of T-cell-based therapy are available for refractory or relapsing diffuse large B-cell lymphoma (DLBCL): CAR T cells and bispecific antibodies. While CAR T cells have revolutionized individualized medicine…
View Post 3 min This content is machine translated Hematology and oncology The one-size-fits-all approach is history, personalized medicine is the future The pursuit of individuality was the focus of this year’s Congress of Oncology and Hematology in Switzerland. This paradigm shift is set to change patients’ lives and redefine cancer treatment.…
View Post 4 min This content is machine translated Immuno-oncological therapies CAR-T cell therapy for hematologic cancers Immunotherapies are now established pillars in the treatment of cancer. The principle of CAR-T cell therapy is that the body’s own T cells are programmed to destroy cancer cells through…
View Post 4 min This content is machine translated Lymphomas and solid tumors New therapeutic approaches achieve first promising results The AACR Annual Meeting is where the cancer research community comes together to explore and push the boundaries of science in search of the next breakthroughs in cancer treatment. This…
View Post 4 min This content is machine translated Immunotherapies CAR-T for pemphigus vulgaris as a future therapeutic option? In recent years, great progress has been made in the study of autologous immunocellular therapies. The development of a target-specific chimeric antigen receptor (CAR) against pathogenetic autoreactive B-cell pemphigus vulgaris…
